Crown Laboratories will operate under the name Revance, effective immediately.
This change follows Crown’s recent acquisition of Revance Therapeutics, Inc.
“The transition to the Revance name marks an exciting new chapter for our company, representing the future of our combined portfolio of advanced, science-driven brands that are designed to address the ever-changing needs of patients, clinicians, and consumers worldwide,” says Jeff Bedard, CEO of Revance, in a news release.
Bedard continues, “By uniting our complementary market-leading products and incredibly talented teams under one powerful brand, we are strengthening our unique position in the marketplace and unlocking exciting new opportunities for growth. Importantly, our dedication to excellence, innovation, and serving our customers remains unchanged. We look forward to continuing to execute on our successful integration and go-forward strategy, as we aim to become a global leader in injectables, skin quality, and skincare solutions.”
